Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ansufaxine
- Development stage
- Phase 1
- Lead developer
- Luye Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ansufaxine (LY03012) is an orally administered small molecule triple reuptake inhibitor (SNDRI) being developed by Shandong Luye Pharmaceutical. It is designed to inhibit the reuptake of serotonin, norepinephrine, and dopamine, which are key neurotransmitters involved in the descending pain inhibitory system. By increasing the synaptic levels of these monoamines, ansufaxine aims to provide analgesic effects for chronic pain conditions such as diabetic peripheral neuropathic pain, fibromyalgia, and osteoarthritis. As of recent clinical trial registries, it is being evaluated in Phase 1/2 studies for safety, pharmacokinetics, and preliminary efficacy.
- Other names
- ansufaxine hydrochloride
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on ansufaxine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ansufaxine.